Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pyxis OncologyPYXS +13.17%26 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates PYXS with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 735 Biotechnology companies, Pyxis Oncology ranks better than 75.1% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pyxis Oncology had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pyxis Oncology Gross Margin % Related Terms
Pyxis Oncology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Pyxis Oncology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PYXS vs ORMP, CAMP, ALEC: Gross Margin % Comparison
For the Biotechnology subindustry, Pyxis Oncology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pyxis Oncology (PYXS) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Pyxis Oncology and its competitors. Over the past decade, Pyxis Oncology's Gross Margin % has ranged from 82.77 to 97.06. According to the industry distribution chart, Pyxis Oncology ranks #183 out of 735 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Pyxis Oncology's Gross Margin % too high?
Pyxis Oncology's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 82.77 to a high of 97.06. Based on the distribution chart, Pyxis Oncology ranks #183 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pyxis Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Pyxis Oncology's Gross Margin % compare to ORMP and CAMP?
According to the Biotechnology industry distribution chart, Pyxis Oncology ranks #183 out of 735 companies for Gross Margin %. This places Pyxis Oncology in the top 25% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Historically, Pyxis Oncology's own Gross Margin % has ranged from 82.77 to 97.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pyxis Oncology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pyxis Oncology's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pyxis Oncology stock overvalued right now?
Pyxis Oncology (PYXS) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Pyxis Oncology's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pyxis Oncology (PYXS), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
26GF Score
Get the complete analysis for PYXS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PYXS has been successfully added to your 
